Author Archives: Bruno Quinney

#10x Genomics #Asia #Cancer research #Pacific

10x Genomics launches international cancer research project 

Life sciences company 10x Genomics has launched an initiative to create a pan-cancer spatial atlas driven by spatial research in the Asia-Pacific region.  As part of the initiative, 10x Genomics has partnered with the Garvan Institute of Medical Research in Australia and the University of Tokyo in… Read More

#Cancer Research #News

Stem cell transplant
#Gene therapy #Hunter Syndrome #The University of Manchester

Revolutionary therapy treats Hunter syndrome for first time 

A world-first therapy has provided an unprecedented step towards treating the devastating condition Hunter syndrome.  Researchers at the University of Manchester treated a three-year-old boy, Ollie Chu, with a stem cell gene therapy treatment developed by the university. Several months on from the procedure performed in… Read More

#News

#Antimicrobial resistance (AMR) #Bacteria #Cancer research #CAR T-cell therapy #GSK #Gut microbiome #Lung cancer #Oncology #Osteosarcoma #UK government

DDW Highlights: 25 November 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research into bacterial species and diseases broke new ground. Elsewhere, vaccines could… Read More

#Podcasts

Scientist in laboratory
#Biotechnology #Cancer research #Clinical trial

First patient dosed in trial of MTHFD1/2 inhibitor  

The first patient has been dosed in the Phase I/II clinical trial of a MTHFD1/2 inhibitor to treat advanced solid tumours, biotechnology company One-carbon Therapeutics has announced.  TH9619, a first-in-class, potent, small-molecule, and a dual inhibitor of MTHFD1/2. TH9619 kills cancer cells via a dual mechanism of… Read More

#News

Red blood cells
#blood #FDA #Grifols

FDA approves label expansion to treat blood-clotting disorder 

The US Food and Drug Administration (FDA) has approved an expanded indication for Thrombate III, the Grifols-developed drug treating a rare blood-clotting disorder.  Thrombate III is used to prevent hereditary antithrombin deficiency (hATd), becoming the only antithrombin concentrate (ATc) to be approved in both adult and paediatric patients.  The decision by the FDA follows the… Read More

#News #Regulatory

Blood tests in laboratory
#Crohn's disease #European Commission #Ulcerative colitis (UC)

World’s first liquid infliximab formulation approved for market 

The European Commission (EC) has granted marketing authorisation for the world’s first liquid formulation of infliximab.  Remsima is an intravenous liquid formulation used to treat autoimmune diseases including Crohn’s disease and ulcerative colitis. Remsima was first approved in September 2013 and launched in major EU countries in 2015 as a… Read More

#News

#Antimicrobial resistance (AMR) #Bacteria #Cancer research #CAR T-cell therapy #GSK #Gut microbiome #Lung cancer #Nuclear medicine #Oncology #Osteosarcoma #UK government

This week in Drug Discovery (17 – 21 November) 

News round-up for 17 – 21 November by Bruno Quinney, Content Team at DDW.  This week in DDW, research into bacterial species and diseases gets top billing. Elsewhere, vaccines could offer groundbreaking solutions to cervical and lung cancer.  The top stories:    Medication detrimental to gut microbiome,… Read More

#News

#Cancer research #Mosaic Therapeutics

Mosaic Therapeutics appoints Dr Stephen Shuttleworth as CSO 

Mosaic Therapeutics has announced the appointment of Dr Stephen Shuttleworth as Chief Scientific Officer.  Shuttleworth has been a Venture Partner at Samsara BioCapital, Palo Alto, US since 2019, where his responsibilities included R&D due diligence, new company creation and C-suite level company leadership. He previously served as CSO, COO and… Read More

#News

Human liver
#Genomics #GSK #Liver disease #Ochre Bio

Ochre Bio and GSK complete early research into human liver 

Biotechnology company Ochre Bio has completed research into human liver functional genomics and single-cell datasets, following a partnership with GSK.  Results include a large-scale functional genomics data from research into primary human hepatocytes and a single-cell dataset built from perfused human donor livers.  Ochre’s research… Read More

#News

Close up of vaccine syringe
#Asthma #Cold Urticaria #European Commission

Omlyclo set for line extension after EC approval 

The European Commission (EC) has granted a line extension in the European Union for Omlyclo (omalizumab), Europe’s first and only omalizumab biosimilar.  The EC approved Omlyclo 300mg/2ml prefilled syringe, following approval for 75mg/0.5ml and 150mg/1ml solutions in May 2024.  Omlyclo is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with… Read More

#News #Regulatory

Osteoarthritis
#Arthritis #Investment #Sanofi

Sanofi backs Lifordi with investment for arthritis trial

Sanofi Ventures has invested in biotechnology company Lifordi Therapeutics, bringing Lifordi’s total financing round up to $112 million.  The funding is set to be used to support an ongoing Phase I study in Rheumatoid Arthritis (RA) by evaluating LFD-200, an ADC delivering a potent glucocorticoid (GC) directly to immune cells. It also provides for… Read More

#Business & Investment #News

Cancer cells
#Cancer research #GSK #Immuno-oncology

GSK partners with LTZ to develop myeloid cell engagers 

GSK has announced a strategic collaboration with biotechnology company LTZ to advance novel myeloid cell engagers (MCEs) in oncology.   The research collaboration aims to develop up to four potential first-in-class MCE therapies targeting haematologic cancers and solid tumours. The agreement grants GSK an exclusive option to license worldwide development and commercial rights… Read More

#Business & Investment #News

Diffuse large B-cell lymphoma
#Clinical trial #EMA #Follicular lymphoma

EMA issues positive CHMP opinion on Minjuvi 

The European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi (tafasitamab) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).  The positive opinion was issued by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The opinion is based on data from… Read More

#News #Regulatory

Organoids
#Cancer research #Organoids

ChristianaCare launches first-of-its-kind organoid core 

US healthcare organisation ChristianaCare has launched a first-of-its-kind organoid core to personalise cancer treatment. The organoid core was unveiled at ChristianaCare’s Cawley Center for Translational Cancer Research, with a new laboratory facility in the Helen F Graham Cancer Center & Research Institute. The new facility will be used to grow… Read More

#News

Knee x-ray
#Cancer research #CAR-T #Osteosarcoma

OSI awards $1.5 million to advance osteosarcoma treatments 

The Osteosarcoma Institute (OSI) has awarded over $1.5 million in research funding to four projects aiming to advance the treatment of osteosarcoma.  The OSI, which works to increase treatment options and survival rates in osteosarcoma patients, has awarded sums between $125,000 and $500,000 to projects in the field.  OSI Director Dr Lee Helman… Read More

#Business & Investment #News

#Biopharma #Business #Neurology

Relief Therapeutics and NeuroX to combine in new company 

Biotechnology company Relief Therapeutics has announced a business combination with commercial-stage company NeuroX to create a new digital neurotherapeutics company.  The business combination follows approval from Relief’s shareholders, who have also approved a capital increase through the issuance of 140 million new ordinary shares.   The business combination is expected to close in December… Read More

#Business & Investment #News